L-tLeu-gly-OCH3 | 84907-92-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-tLeu-gly-OCH3
• 英文别名: L-tert-Leu-Gly-OCH3；methyl 2-[[(2S)-2-amino-3,3-dimethylbutanoyl]amino]acetate
• CAS: 84907-92-6
• 化学式: C₉H₁₈N₂O₃
• 分子量: 202.254
• InChiKey: ZNUSEIODWOBHTA-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  L-tLeu-gly-OCH3 在 正丁基锂 作用下， 以 二氯甲烷 、 xylene 为溶剂， 反应 116.25h， 生成 (2R,5S)-2-Benzyl-5-tert-butyl-3,6-dimethoxy-2,5-dihydro-pyrazine
  参考文献：
  名称：

  Schoellkopf, Ulrich; Neubauer, Hans-Juergen, Synthesis, 1982, # 10, p. 861 - 864

  摘要：

  DOI：
• 作为产物：
  描述：

  L-叔亮氨酸 生成 L-tLeu-gly-OCH3
  参考文献：
  名称：

  通过2,5-二酮哌嗪的金属化双内酰胺醚对非蛋白质氨基酸的对映选择性合成

  摘要：

  2,5-二酮哌嗪的双-内酯醚1包含一个手性诱导中心，一个酸性CH键和两个易于水解的位点。他们用BuLi反应以得到类型的锂化合物4，15，19或32，其具有前手性的C原子。他们很容易添加亲电试剂（例如烷基化剂或羰基化合物），具有非同寻常的非对映异构性。在许多情况下，加合物的减值（de =非对映异构体过量=不对称诱导）超过95％。水解时，加合物被裂解释放出手性助剂（用于构建双内酰胺醚1）和目标分子，即8型旋光氨基酸甲基酯，19，25或36。两种氨基酸酯可通过分馏或（最终在进一步水解成氨基酸后）通过色谱法分离。讨论了过渡状态模型，该模型可以解释异常高的不对称诱导和诱导构型的可预测性。

  DOI：

  10.1016/s0040-4020(01)91926-x

文献信息

• Functionalization of Sulfonamide-Containing Peptides through Late-Stage Palladium-Catalyzed C(sp³)–H Arylation
  作者：Qingqing Bai、Jian Tang、Huan Wang

  DOI：10.1021/acs.orglett.9b01953

  日期：2019.8.2

  Bioactive peptides are emerging as promising candidates of clinic therapeutics. Here, we report a method for late-stage functionalization of sulfonamide-containing peptides through Pd-catalyzed C(sp3)–H arylation. In this protocol, the backbones of N-sulfonated peptides act as directing groups, which allows site-specific arylation of benzylsulfonamide moiety. This chemistry exhibits broad substrate

  生物活性肽正在成为临床疗法的有希望的候选者。在这里，我们报告了一种通过Pd催化的C（sp 3）–H芳基化对含磺酰胺肽进行后期官能化的方法。在该方案中，N-磺化肽的主链充当引导基团，其允许位点特异性芳基化苄基磺酰胺部分。这种化学方法具有广泛的底物范围，可用于合成肽-肽和肽-氨基酸缀合物。我们的研究结果突显了拟肽骨架在促进Pd催化功能化方面的潜力。
• Structure-based design and optimization of potent inhibitors of the adenoviral protease
  作者：Philipp Grosche、Finton Sirockin、Aengus Mac Sweeney、Paul Ramage、Paul Erbel、Samu Melkko、Anna Bernardi、Nicola Hughes、David Ellis、Keith D. Combrink、Nadine Jarousse、Eva Altmann

  DOI：10.1016/j.bmcl.2014.12.057

  日期：2015.2

  Adenoviral infections are associated with a wide range of acute diseases, among which ocular viral conjunctivitis (EKC) and disseminated disease in immunocompromised patients. To date, no approved specific anti-adenoviral drug is available, but there is a growing need for an effective treatment of such infections. The adenoviral protease, adenain, plays a crucial role for the viral lifecycle and thus represents an attractive therapeutic target. Structure-guided design with the objective to depeptidize tetrapeptide nitrile 1 led to the novel chemotype 2. Optimization of scaffold 2 resulted in picomolar adenain inhibitors 3a and 3b. In addition, a complementary series of irreversible vinyl sulfone containing inhibitors were rationally designed, prepared and evaluated against adenoviral protease. High resolution X-ray co-crystal structures of representatives of each series proves the successful design of these inhibitors and provides an excellent basis for future medicinal chemistry optimization of these compounds. (C) 2014 Elsevier Ltd. All rights reserved.
• METHODS AND COMPOSITIONS FOR PERFORMING CONTINUOUS DIRECTED EVOLUTION
  申请人：Massachusetts Institute of Technology

  公开号：US20190153472A1

  公开（公告）日：2019-05-23

  Disclosed herein are methods of performing continuous directed evolution in complex biological systems, including metazoan cells. These methods include the infection of engineered, non-naturally occurring metazoan cells with engineered, non-naturally occurring DNA viruses. The generation of infectious viruses that can infect new cells depends on the evolution of a gene of interest which is driven by an error-prone adenoviral polymerase. Also disclosed herein, are the compositions of engineered, non-naturally occurring metazoan cells and engineered, non-naturally occurring DNA viruses that function as components in the continuous directed evolution methodologies.
• [EN] INDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDAZOLE
  申请人：PFIZER

  公开号：WO2009106980A2

  公开（公告）日：2009-09-03

  This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of Formula (I): wherein R1, R2 and R3 are as defined in this specification.